Aktis Oncology, Inc. (AKTS) Q3 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Aktis Oncology, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.049 -- 00:00:05.510 Good day, ladies and gentlemen, and welcome to the Acoustis Technologies fiscal 2024 00:00:05.510 -- 00:00:10.932 third quarter conference call. As a reminder, this conference is being recorded. 00:00:10.932 -- 00:00:15.573 At the conclusion of the company presentation, Acoustis management will take questions. 00:00:15.573 -- 00:00:20.354 To ask a question, please press star 1 on your telephone keypad to be placed into the 00:00:20.354 -- 00:00:25.075 queue. A replay of the call will be available on the investor relations section of the 00:00:25.075 -- 00:00:28.223 Acoustis website. Thank you. 00:00:28.223 -- 00:00:31.446 Thank you, Operator, and good morning to everyone on the call. 00:00:31.446 -- 00:00:35.949 Welcome to Acousis' third quarter fiscal 2024 conference call. 00:00:35.949 -- 00:00:41.674 I am Ken Bowler, CFO, and I'm joined today by our founder and CEO, Jeff Shealy, 00:00:41.674 -- 00:00:47.919 Corporate General Counsel, Drew Wright, and EDP of Business Development, Dave Eichle. 00:00:47.919 -- 00:00:52.343 Before we begin, please note that today's presentation includes forward-looking statements 00:00:52.343 -- 00:00:54.514 about our business outlook. 00:00:54.514 -- 00:00:58.616 All statements other than statements of historical facts included in this conference 00:00:58.616 -- 00:01:03.618 call, such as expectations regarding our strategies and operations, including 00:01:03.618 -- 00:01:08.961 the timing and prospects of product development and customer orders and design wins, 00:01:08.961 -- 00:01:14.323 possible collaborative or partnering relationships, litigation matters, and expected 00:01:14.323 -- 00:01:18.765 financial and operating results, are forward-looking statements. 00:01:18.765 -- 00:01:23.027 Suc...